Cargando…

Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study

BACKGROUND: Herein, we analyzed the efficacy of main antibiotic therapy regimens in the treatment of healthcare-associated meningitis (HCAM). MATERIALS/METHODS: This retrospective cohort study was conducted in 18 tertiary-care academic hospitals Turkey, India, Egypt and Romania. We extracted data an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sipahi, Oguz Resat, Akyol, Deniz, Ormen, Bahar, Cicek-Senturk, Gonul, Mermer, Sinan, Onal, Ugur, Amer, Fatma, Saed, Maysaa Abdallah, Ozdemir, Kevser, Tukenmez-Tigen, Elif, Oztoprak, Nefise, Altin, Ummugulsum, Kurtaran, Behice, Popescu, Corneliu Petru, Sakci, Mustafa, Suntur, Bedia Mutay, Gautam, Vikas, Sharma, Megha, Kaya, Safak, Akcil, Eren Fatma, Kaya, Selcuk, Turunc, Tuba, Ergen, Pınar, Kandemir, Ozlem, Cesur, Salih, Bardak-Ozcem, Selin, Ozgiray, Erkin, Yurtseven, Taskın, Erdem, Huseyin Aytac, Sipahi, Hilal, Arda, Bilgin, Pullukcu, Hüsnü, Tasbakan, Meltem, Yamazhan, Tansu, Aydemir, Sohret, Ulusoy, Sercan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540455/
https://www.ncbi.nlm.nih.gov/pubmed/37770836
http://dx.doi.org/10.1186/s12879-023-08596-z
_version_ 1785113723322499072
author Sipahi, Oguz Resat
Akyol, Deniz
Ormen, Bahar
Cicek-Senturk, Gonul
Mermer, Sinan
Onal, Ugur
Amer, Fatma
Saed, Maysaa Abdallah
Ozdemir, Kevser
Tukenmez-Tigen, Elif
Oztoprak, Nefise
Altin, Ummugulsum
Kurtaran, Behice
Popescu, Corneliu Petru
Sakci, Mustafa
Suntur, Bedia Mutay
Gautam, Vikas
Sharma, Megha
Kaya, Safak
Akcil, Eren Fatma
Kaya, Selcuk
Turunc, Tuba
Ergen, Pınar
Kandemir, Ozlem
Cesur, Salih
Bardak-Ozcem, Selin
Ozgiray, Erkin
Yurtseven, Taskın
Erdem, Huseyin Aytac
Sipahi, Hilal
Arda, Bilgin
Pullukcu, Hüsnü
Tasbakan, Meltem
Yamazhan, Tansu
Aydemir, Sohret
Ulusoy, Sercan
author_facet Sipahi, Oguz Resat
Akyol, Deniz
Ormen, Bahar
Cicek-Senturk, Gonul
Mermer, Sinan
Onal, Ugur
Amer, Fatma
Saed, Maysaa Abdallah
Ozdemir, Kevser
Tukenmez-Tigen, Elif
Oztoprak, Nefise
Altin, Ummugulsum
Kurtaran, Behice
Popescu, Corneliu Petru
Sakci, Mustafa
Suntur, Bedia Mutay
Gautam, Vikas
Sharma, Megha
Kaya, Safak
Akcil, Eren Fatma
Kaya, Selcuk
Turunc, Tuba
Ergen, Pınar
Kandemir, Ozlem
Cesur, Salih
Bardak-Ozcem, Selin
Ozgiray, Erkin
Yurtseven, Taskın
Erdem, Huseyin Aytac
Sipahi, Hilal
Arda, Bilgin
Pullukcu, Hüsnü
Tasbakan, Meltem
Yamazhan, Tansu
Aydemir, Sohret
Ulusoy, Sercan
author_sort Sipahi, Oguz Resat
collection PubMed
description BACKGROUND: Herein, we analyzed the efficacy of main antibiotic therapy regimens in the treatment of healthcare-associated meningitis (HCAM). MATERIALS/METHODS: This retrospective cohort study was conducted in 18 tertiary-care academic hospitals Turkey, India, Egypt and Romania. We extracted data and outcomes of all patients with post-neurosurgical meningitis cases fulfilling the study inclusion criteria and treated with empirical therapy between December 2006-September 2018. RESULTS: Twenty patients in the cefepime + vancomycin-(CV) group, 31 patients in the ceftazidime + vancomycin-(CFV) group, and 119 patients in the meropenem + vancomycin-(MV) group met the inclusion criteria. The MV subgroup had a significantly higher mean Glasgow Coma Score, a higher rate of admission to the intensive care unit within the previous month, and a higher rate of antibiot herapy within the previous month before the meningitis episode (p < 0.05). Microbiological success on Day 3–5, end of treatment (EOT) clinical success (80% vs. 54.8%% vs 57.9%), and overall success (EOT success followed by one-month survival without relapse or reinfection 65% vs. 51.6% vs. 45.3%), EOT all cause mortality (ACM) and day 30 ACM (15% vs. 22.6% vs. 26%) did not differ significantly (p > 0.05) among the three cohorts. No regimen was effective against carbapenem-resistant bacteria, and vancomycin resulted in an EOT clinical success rate of 60.6% in the methicillin-resistant staphylococci or ampicillin-resistant enterococci subgroup (n = 34). CONCLUSIONS: Our study showed no significant difference in terms of clinical success and mortality among the three treatment options. All regimens were ineffective against carbapenem-resistant bacteria. Vancomycin was unsuccessful in approximately 40% of cases involving methicillin-resistant staphylococci or ampicillin-resistant enterococci.
format Online
Article
Text
id pubmed-10540455
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105404552023-09-30 Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study Sipahi, Oguz Resat Akyol, Deniz Ormen, Bahar Cicek-Senturk, Gonul Mermer, Sinan Onal, Ugur Amer, Fatma Saed, Maysaa Abdallah Ozdemir, Kevser Tukenmez-Tigen, Elif Oztoprak, Nefise Altin, Ummugulsum Kurtaran, Behice Popescu, Corneliu Petru Sakci, Mustafa Suntur, Bedia Mutay Gautam, Vikas Sharma, Megha Kaya, Safak Akcil, Eren Fatma Kaya, Selcuk Turunc, Tuba Ergen, Pınar Kandemir, Ozlem Cesur, Salih Bardak-Ozcem, Selin Ozgiray, Erkin Yurtseven, Taskın Erdem, Huseyin Aytac Sipahi, Hilal Arda, Bilgin Pullukcu, Hüsnü Tasbakan, Meltem Yamazhan, Tansu Aydemir, Sohret Ulusoy, Sercan BMC Infect Dis Research BACKGROUND: Herein, we analyzed the efficacy of main antibiotic therapy regimens in the treatment of healthcare-associated meningitis (HCAM). MATERIALS/METHODS: This retrospective cohort study was conducted in 18 tertiary-care academic hospitals Turkey, India, Egypt and Romania. We extracted data and outcomes of all patients with post-neurosurgical meningitis cases fulfilling the study inclusion criteria and treated with empirical therapy between December 2006-September 2018. RESULTS: Twenty patients in the cefepime + vancomycin-(CV) group, 31 patients in the ceftazidime + vancomycin-(CFV) group, and 119 patients in the meropenem + vancomycin-(MV) group met the inclusion criteria. The MV subgroup had a significantly higher mean Glasgow Coma Score, a higher rate of admission to the intensive care unit within the previous month, and a higher rate of antibiot herapy within the previous month before the meningitis episode (p < 0.05). Microbiological success on Day 3–5, end of treatment (EOT) clinical success (80% vs. 54.8%% vs 57.9%), and overall success (EOT success followed by one-month survival without relapse or reinfection 65% vs. 51.6% vs. 45.3%), EOT all cause mortality (ACM) and day 30 ACM (15% vs. 22.6% vs. 26%) did not differ significantly (p > 0.05) among the three cohorts. No regimen was effective against carbapenem-resistant bacteria, and vancomycin resulted in an EOT clinical success rate of 60.6% in the methicillin-resistant staphylococci or ampicillin-resistant enterococci subgroup (n = 34). CONCLUSIONS: Our study showed no significant difference in terms of clinical success and mortality among the three treatment options. All regimens were ineffective against carbapenem-resistant bacteria. Vancomycin was unsuccessful in approximately 40% of cases involving methicillin-resistant staphylococci or ampicillin-resistant enterococci. BioMed Central 2023-09-28 /pmc/articles/PMC10540455/ /pubmed/37770836 http://dx.doi.org/10.1186/s12879-023-08596-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sipahi, Oguz Resat
Akyol, Deniz
Ormen, Bahar
Cicek-Senturk, Gonul
Mermer, Sinan
Onal, Ugur
Amer, Fatma
Saed, Maysaa Abdallah
Ozdemir, Kevser
Tukenmez-Tigen, Elif
Oztoprak, Nefise
Altin, Ummugulsum
Kurtaran, Behice
Popescu, Corneliu Petru
Sakci, Mustafa
Suntur, Bedia Mutay
Gautam, Vikas
Sharma, Megha
Kaya, Safak
Akcil, Eren Fatma
Kaya, Selcuk
Turunc, Tuba
Ergen, Pınar
Kandemir, Ozlem
Cesur, Salih
Bardak-Ozcem, Selin
Ozgiray, Erkin
Yurtseven, Taskın
Erdem, Huseyin Aytac
Sipahi, Hilal
Arda, Bilgin
Pullukcu, Hüsnü
Tasbakan, Meltem
Yamazhan, Tansu
Aydemir, Sohret
Ulusoy, Sercan
Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study
title Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study
title_full Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study
title_fullStr Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study
title_full_unstemmed Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study
title_short Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study
title_sort empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter ephesus study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540455/
https://www.ncbi.nlm.nih.gov/pubmed/37770836
http://dx.doi.org/10.1186/s12879-023-08596-z
work_keys_str_mv AT sipahioguzresat empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT akyoldeniz empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT ormenbahar empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT ciceksenturkgonul empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT mermersinan empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT onalugur empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT amerfatma empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT saedmaysaaabdallah empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT ozdemirkevser empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT tukenmeztigenelif empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT oztopraknefise empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT altinummugulsum empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT kurtaranbehice empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT popescucorneliupetru empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT sakcimustafa empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT sunturbediamutay empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT gautamvikas empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT sharmamegha empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT kayasafak empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT akcilerenfatma empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT kayaselcuk empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT turunctuba empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT ergenpınar empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT kandemirozlem empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT cesursalih empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT bardakozcemselin empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT ozgirayerkin empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT yurtseventaskın empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT erdemhuseyinaytac empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT sipahihilal empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT ardabilgin empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT pullukcuhusnu empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT tasbakanmeltem empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT yamazhantansu empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT aydemirsohret empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy
AT ulusoysercan empiricalcefepimevancomycinversusceftazidimevancomycinversusmeropenemvancomycininthetreatmentofhealthcareassociatedmeningitisresultsofthemulticenterephesusstudy